Tuberculosis Treatment: The Evidence Behind the Pathway

A 34-year-old construction worker from Ballari has had a cough for two months and has lost a lot of weight. His sputum is positive, and the test shows no resistance. He weighs 42 kg. His wife and their two children live with him in one room. You write the prescription, and he asks the question many patients ask: “Doctor, what should I eat?” This is an illustrative case, not a real patient.

By the end of this article you will know why that question is part of the treatment, and how the tool turns his weight into his tablets.

1. Food Is Part of the Treatment

Undernutrition is the single leading driver of TB mortality in India. “Is that only an association?” Not any more. The tool used to give the trial that settled it:

The RATIONS trial (Bhargava et al., Lancet 2023) showed that supplementing the household contacts of a patient with pulmonary tuberculosis reduced their tuberculosis incidence by 39% for all forms and 48% for microbiologically confirmed pulmonary disease. In the patient cohort nested in the same trial (Lancet Glob Health 2023), a 5% weight gain by two months was associated with an adjusted hazard ratio for death of 0.39.

Look at what those two numbers mean for our patient. A hazard ratio of 0.39 means that patients who gained 5% of their weight by two months had well under half the hazard of death of those who did not, after adjustment. And his wife and children, as household contacts, are the people the first half of the trial was about. That is why the tool treats specific macro- and micro-nutritional targets alongside ATT as a standard of care, not optional supportive therapy. Its Nutrition tab works out the targets from his age, sex, weight and height.

2. From His Weight to His Tablets

NTEP doses first-line drugs in fixed-dose combinations (FDCs) by weight band. The bands are calibrated to deliver therapeutic mg/kg doses across the range of body weights each one covers:

At 42 kg he takes 3 adult FDCs. If he gains 8 kg, he crosses into the next band and needs 4. A child or adolescent up to 18 years weighing under 40 kg is dosed on the paediatric bands; above 39 kg they move to the adult bands.

3. What Each Drug Does to the Patient: RIPE

• Rifampicin: red or orange secretions, and rapid induction of CYP450, the most potent inducer in clinical medicine.
• Isoniazid: peripheral neuropathy, so always give vitamin B6, and hepatitis.
• Pyrazinamide: polyarthralgia from hyperuricaemia, and the most potent hepatotoxin of the four.
• Ethambutol: retrobulbar optic neuritis and red-green colour blindness. Baseline visual acuity is mandatory.

Warn him about the orange urine before he sees it. A patient who thinks his kidneys are bleeding may stop the tablets.

4. When the Liver Objects

“His ALT is twice normal at two weeks. Do I stop?” No. Stop all ATT when the AST or ALT exceeds 5 times the upper limit of normal without symptoms, or 3 times with symptoms of hepatitis (nausea, vomiting, anorexia, jaundice). Then wait until the liver tests normalise or fall below twice normal and the symptoms resolve.

Reintroduce the drugs one at a time, with 3 to 7 days between each: rifampicin first, as the least hepatotoxic, then isoniazid, then pyrazinamide last. If hepatitis recurs with one drug, omit it permanently and substitute. Never rechallenge pyrazinamide if it was the culprit; extend the treatment instead. The tool links to its ATT-Induced Liver Injury and Rechallenge pathway for the bridging regimen and the dates.

5. Why a Private-Sector FDC Can Fail

Substandard generic FDCs in the private sector frequently fail to deliver adequate rifampicin because of poor formulation. If a patient is failing therapy on private-sector FDCs, strongly consider switching to NTEP-supplied FDCs or to individual loose drugs. This is a recognised cause of acquired drug resistance.

Food matters here too. A meal blunts the peak level of rifampicin, and the low peak that follows is one of the routes to acquired resistance. Bedaquiline goes the other way: absorption increases nearly two-fold with a high-fat meal. So “what should I eat?” has a second answer: when.

6. When It Is Not Drug-Susceptible

The NTEP 2025 definitions run in steps: H mono or poly resistance (resistant to isoniazid, susceptible to rifampicin, confirmed on FL-LPA); MDR/RR-TB (resistant to rifampicin, susceptible to fluoroquinolones); pre-XDR (with resistance to any fluoroquinolone); and XDR (with resistance to bedaquiline and/or linezolid as well). NTEP prioritises the shorter all-oral regimens, BPaLM for MDR and BPaL for pre-XDR. Both are strictly contraindicated below 14 years of age and in severe extrapulmonary TB, and the tool then routes the patient to the 18 to 20 month longer oral regimen.

Back to Our Patient

He takes 3 adult FDCs, timed against food as the tool prints for each drug, with vitamin B6, after a baseline check of his vision. He is told to expect orange urine. His nutrition is prescribed, not suggested, and his weight is checked at two months, because a 5% gain is a measure of how he will do. His wife and children are screened, and the family’s food is part of the conversation.

Try This

A 16-year-old girl with pulmonary TB weighs 38 kg. How is she dosed? Illustrative case.

Answer. She is under 18 and under 40 kg, so she is dosed on the paediatric bands, not the adult ones. At 38 kg she falls in the mixed band of 30 to 39 kg: 2 paediatric plus 2 adult FDCs. Once she weighs more than 39 kg, she moves to the adult bands.

Take-Home Points

• Nutritional targets alongside ATT are a standard of care, not optional supportive therapy.
• Weigh the patient at every visit: a change of band changes the dose.
• Always give vitamin B6 with isoniazid, and check vision before ethambutol.
• Stop all ATT at 5 times the upper limit without symptoms, or 3 times with them; rechallenge rifampicin first.
• A patient failing on private-sector FDCs may need NTEP-supplied FDCs or loose drugs.

For the danger of feeding a starved patient too fast, see Refeeding Syndrome: The Evidence Behind the Pathway; for a fever that is not yet a diagnosis, Pyrexia of Unknown Origin: The Evidence Behind the Pathway.

Declaration: the author built and maintains the tool. It is free to use. The figures in this article are those the tool carried in its Nutrition and Evidence tabs on 5 November 2026, each from the source the tool names. The illustrative cases follow the tool’s rules; check the tool’s result for a real patient.

References

1. Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. National Guidelines for Management of Drug Resistant Tuberculosis. New Delhi: MoHFW; 2025.
2. Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. Guidelines for Programmatic Management of Drug Susceptible Tuberculosis. New Delhi: MoHFW; 2024.
3. Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. Guidance Document on Nutritional Care and Support for TB Patients in India. New Delhi: MoHFW; 2024.
4. Bhargava A, Bhargava M, Meher A, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet. 2023;402(10402):627-640.
5. Bhargava A, Bhargava M, Meher A, et al. Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. Lancet Glob Health. 2023;11(9):e1402-e1411.
6. Bhargava A, Chatterjee M, Jain Y, et al. Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PLoS One. 2013;8(10):e77979.
7. Central Tuberculosis Division, Ministry of Health and Family Welfare, Government of India. Guidelines for Programmatic Management of Tuberculosis Preventive Treatment in India. New Delhi: MoHFW; 2021, with the 2024 addenda on the 1HP and 3RH regimens.
8. Indian Council of Medical Research. Standard Treatment Workflow: Drug Sensitive-TB Treatment as per NTEP. New Delhi: ICMR; 18 March 2022.
9. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-952.
10. Nyang’wa BT, Berry C; TB-PRACTECAL Study Group. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331-2343.
11. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO; 2022.